Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age45+
SponsorGrupo Español de Investigación en Diagnóstico y Tratamiento Hipertemprano de Enfermedades (GeDiTPhe)

About this trial

This research is a clinical performance study of in vitro diagnostic device (IVD), a prospective, multicentre, open-label, case-control clinical investigation aimed at constructing a predictive model that allows results to be classified as positive or negative in relation to the probability of having lung cancer.

Eligibility criteria

Qualifiers

Person aged 45 years or older at the time of signing the consent form.

Person with a current anatomopathologically confirmed diagnosis of small-cell or non-small cell lung cancer.

Not having received any oncological treatment prior to sample collection (surgery, radiotherapy, or systemic treatment with chemotherapy or immunotherapy).

Person aged 45 years or older at the time of signing the consent form.

Disqualifiers

History of any malignant neoplasm, except for subjects with tumors in localized stages who have undergone radical treatment and have been disease-free for at least five years.

Patient diagnosed with lung cancer who has already started oncological treatment before sample collection.

Patient who has undergone a biopsy or any invasive procedure or minor surgery less than 48 hours ago.

Patient who has undergone major surgery less than 7 days ago.

Trial design

Treatments tested in this trial

  • Blood sample collection for telomere biomarker analysis
  • Telomere biomarker analysis

Treatment groups

1,200 Participants
are divided into 2 treatment groups

Sponsors and collaborators